| Phase 2/3 |
| NCT07756008 |
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic… |
Bladder Urothelial Carcinoma |
Not Yet Recruiting |
| Phase 2 |
| NCT06739395 |
Precision Medicine Trial Based on Molecular Matching Therapy for Patients With Standard… |
Solid Tumor |
Recruiting |
| NCT07125547 |
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral… |
Ureteral Cancer |
Recruiting |
| NCT07126119 |
Neoadjuvant Tislelizumab in Combination With Nab-Paclitaxel for UTUC |
Upper Tract Urothelial Carcinoma |
Recruiting |
| NCT07170293 |
Phase II Trial of Tunlametinib in Patients With NRAS Mutant Non-melanoma Refractory Solid… |
Solid Cancers |
Recruiting |
| NCT07172386 |
Preoperative Therapy of Super-selective Tumor Artery Embolization Combined With… |
Renal Cell Carcinoma (RCC) |
Recruiting |
| NCT07179783 |
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive… |
Prostate Cancer (Adenocarcinoma) |
Recruiting |
| NCT07233252 |
Nephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer |
Renal Pelvic Carcinoma |
Recruiting |
| NCT07475403 |
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk… |
Bladder Cancer |
Recruiting |
| NCT05837806 |
Efficacy and Safety of Tislelizumab in Combination With Disitamab-vedotin as Neoadjuvant… |
Neoadjuvant Immunotherapy |
Recruiting |
| NCT07712029 |
Phase II Study of Becotatug Vedotin Plus Pucotenlimab for Advanced Refractory Solid… |
Advanced Refractory Solid Tumors |
Recruiting |
| NCT06584435 |
A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer |
High-risk Renal Cell Carcinoma |
Active, Not Recruiting |
| NCT07625527 |
Is Prolonged Systemic Immunotherapy Necessary After Achieving Tumor-free Status in… |
Bladder (Urothelial, Transitional Cell) Cancer |
Not Yet Recruiting |
| Phase 1/2 |
| NCT06663007 |
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With… |
Prostate Cancer |
Recruiting |
| NCT06895733 |
Study of Pazopanib Combined With Palbociclib for Refractory Solid Tumors With… |
Solid Tumor, Adult |
Recruiting |
| Not specified |
| NCT06536725 |
Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy… |
Prostate Cancer |
Recruiting |
| NCT07441499 |
Using Liquid Biopsy Testing to Identify, Monitor, Predict Recurrence in Urothelial… |
Urothelial Carcinoma (UC) |
Recruiting |
| NCT07130578 |
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second… |
Bladder Cancer |
Recruiting |
| NCT07180212 |
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk… |
Bladder Cancer |
Recruiting |
| NCT07657325 |
Study on MRD Prediction of Efficacy of Toripalimab in the Treatment of High-risk… |
Renal Cell Carcinoma (RCC) |
Recruiting |
| NCT07321197 |
Radical Nephrectomy With vs Without Template Lymph Node Dissection in High-Risk Renal… |
Renal Cell Carcinoma (Kidney Cancer) |
Recruiting |
| NCT07321210 |
Radical Nephroureterectomy With vs Without Template Lymph Node Dissection in High-Risk… |
Upper Tract Urothelial Carcinoma |
Recruiting |
| NCT07187635 |
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of… |
Bladder Cancer |
Recruiting |
| NCT06954571 |
Imaging-Guided Classification for Endophytic Renal Tumors: PN Strategies & Outcomes |
Renal Tumors |
Active, Not Recruiting |
| NCT07172373 |
Safety and Effectiveness of Antegrade Flexible Ureteroscopy-Assisted Percutaneous… |
Urolithiasis |
Not Yet Recruiting |